Printer Friendly

CORTECH ANNOUNCES 1992 FINANCIAL RESULTS

 DENVER, March 10 /PRNewswire/ -- Cortech Inc. (NASDAQ: CRTQ) today released its financial results for the year ended Dec. 31, 1992. According to David K. Crossen, the company's president and chief executive officer, the company reported a net loss of approximately $4.3 million, or 41 cents per share, compared to a net loss of approximately $4.0 million, or 45 cents per share, for the prior year.
 "These results are consistent with the company's expectations and reflect the company's progress with its clinical trials and drug development programs," Crossen said. Cortech's lead compound, a bradykinin antagonist called Bradycor, was successfully taken through Phase I safety studies in 1992. Although Phase II trials for sepsis with Bradycor have begun, no assurance can be given that the company's therapeutic approaches will lead to successful product launches and product revenues.
 Cortech is a Denver-based biopharmaceutical company focused on the design and development of two novel classes of drugs, bradykinin antagonists and neutrophil elastase inhibitors, to treat a broad range of inflammatory disorders. In addition, Cortech is developing a proprietary potential treatment for allergies and autoimmune diseases. Cortech common stock is listed as CRTQ on NASDAQ.
 -0- 3/10/93
 /CONTACT: David K. Crossen or Joseph L. Turner of Cortech, 303-650-1200/
 (CRTQ)


CO: Cortech Inc. ST: Colorado IN: MTC SU: ERN

MC -- DV003 -- 4879 03/10/93 10:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 10, 1993
Words:226
Previous Article:VOLKSWAGEN OF AMERICA, INC. ANNOUNCES ORGANIZATIONAL CHANGES
Next Article:APACHE ANNOUNCES PUBLIC OFFERING OF 5.3 MILLION SHARES OF COMMON STOCK
Topics:


Related Articles
CORTECH ANNOUNCES INITIAL PUBLIC OFFERING
CORTECH CONVERSION RIGHTS EXPIRE
/C O R R E C T I O N -- CORTECH/
CORTECH FILLS SENIOR POSITIONS
CORTECH AMPLIFIES ITS 1992 FINANCIAL RELEASE
CORTECH RELEASES FIRST QUARTER RESULTS
TO BUSINESS EDITO
CORTECH RELEASES THIRD QUARTER RESULTS
CORTECH ANNOUNCES 1993 FINANCIAL RESULTS
Cortech Announces Second Quarter and Six-Month Financial Results And New Board Member

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters